- RCPT has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $124.1 million.
- RCPT has traded 129,649 shares today.
- RCPT is down 3.4% today.
- RCPT was up 6.9% yesterday.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in RCPT with the Ticky from Trade-Ideas. See the FREE profile for RCPT NOW at Trade-Ideas More details on RCPT: Receptos, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in immune disorders. Currently there are 3 analysts that rate Receptos a buy, no analysts rate it a sell, and none rate it a hold. The average volume for Receptos has been 839,800 shares per day over the past 30 days. Receptos has a market cap of $4.9 billion and is part of the health care sector and drugs industry. Shares are up 27.4% year-to-date as of the close of trading on Tuesday. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE. TheStreetRatings.com Analysis: TheStreet Quant Ratings rates Receptos as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and weak operating cash flow.